2026年美国心脏协会科学会议（AHA 2026）将于11月6日至9日在美国芝加哥盛大召开，为全球医者打造沉浸式学术交流平台。作为大会的重要学术板块，特色科学研究（Featured Science，FS）专场将集中呈现心血管领域多项前沿研究成果，聚焦稳定性
COURAGE – Effect of Percutaneous Coronary Intervention on Long-Term Outcomes in Patients With Stable Ischemic Heart Disease: A 25-Year Follow-Up of the COURAGE Trial
COURAGE试验25年随访：经皮冠状动脉介入治疗（PCI）对稳定性缺血性心脏病患者长期结局的影响
PARAMOUNT – A Randomized Comparison of Personalized Management for Medical and Interventional Therapy Based on Coronary Atherosclerotic Plaque versus Usual Care for Symptomatic Patients With Suspicion of Coronary Artery Disease: Primary Results of the PARAMOUNT Trial
PARAMOUNT试验主要结果： 在有症状的疑似冠状动脉疾病患者中，比较基于冠状
ISCHEMIA-EXTEND – Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease
ISCHEMIA EXTEND试验：稳定性冠状动脉疾病初始侵入性或保守治疗后的长期生存
ISCHEMIA-CKD EXTEND – Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Advanced Chronic Kidney Disease
ISCHEMIA CKD EXTEND试验：晚期慢性
Dynamic Shifts in Cause Specific Mortality After Acute Pulmonary Embolism: A Nationwide Cohort Study
一项全国性队列研究：
ROXI-CATH – Amrecibart and Cenvacibart for the Prevention of Catheter-Related Thrombosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
ROXI CATH Ⅱ期随机、双盲、安慰剂对照试验：Amrecibart与Cenvacibart预防导管相关血栓形成的疗效
HI-PRO – Apixaban vs Placebo to Prevent Recurrences in Provoked Venous Thromboembolism With Enduring Risk Factors: One-Year Extension Results From the HI-PRO Trial
HI-PRO试验的1年延长期结果：与安慰剂相比，
SPEED&PEPS – A 4-Level Clinical Probability-Based Diagnostic Strategy for Suspected Pulmonary Embolism in Emergency Departments: A Cluster-Randomized Trial
SPEED&PEPS整群随机试验：基于四级临床概率的急诊疑似肺栓塞诊断策略
EU-CERT-ICD – Clinical Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators: Late Follow-Up Results of the EU-CERT-ICD Controlled Multi Center Cohort Study
EU-CERT ICD多中心对照试验的远期随访结果：在一级预防患者中，植入植入式心律转复除颤器（ICD）的临床效用
Rethinking Atrial Fibrillation (AF) Burden: AF Density Further Stratifies Heart Failure Risk in a Nationwide Cohort of Patients With Cardiac Devices
重新考虑房颤负荷试验：在植入心脏器械的全国队列中，房颤发作密度可进一步对心衰风险进行分层
Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF
合并队列研究：联合ECG-AI与PREVENT-HF模型，提升短期心衰风险识别能力
Subclinical AF and Stroke: Is There a Safe AF Burden?
亚临床房颤与卒中：是否存在安全的房颤负荷？
First-in-Human Evaluation of BAY 3670549, a Selective GIRK4 Inhibitor for Pharmacological Cardioversion in Patients With Atrial Fibrillation
BAY 3670549选择性GIRK4抑制剂，用于
LATENT – Artificial Intelligence-Guided Electrocardiographic Risk Stratification With Targeted Ambulatory Monitoring for Early Detection of Atrial Fibrillation and Pre-Atrial Fibrillation Atrial Findings: The LATENT Randomized Clinical Trial
LATENT随机临床试验：AI指导
VIHP – Two-Week Helicobacter Pylori Eradication versus Six-Month Pantoprazole for Prevention of Gastrointestinal Bleeding After Percutaneous Coronary Intervention for Acute Coronary Syndrome: The VIHP Randomized Trial
VIHP随机试验：ACS患者PCI后，2周
SWITCH SWEDEHEART – Contemporary Cost-Effectiveness of Default Prasugrel versus Ticagrelor Policies in Acute Coronary Syndromes
SWITCH SWEDEHEART试验：ACS患者使用普拉格雷与
DAPT-SHOCK-AMI – Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor vs. Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction
DAPT-SHOCK-AMI 随机石亚多模态心脏影像亚组：在
PRESCISE-MI – One-Year Outcomes After Implementation of the 0/1-Hour Pathway: A Prespecified Secondary Analysis of a Randomized Controlled Trial
PRESCISE MI随机对照试验的预设次级分析：0/1h诊断路径实施后的1年结局
CHIP-BCIS3 – Periprocedural Myocardial Injury, Microaxial Flow Pump Use and Cardiovascular Death After Complex Percutaneous Coronary Intervention: Insights From a Pre-Specified Analysis of the CHIP-BCIS3 Trial
CHIP-BCIS 3试验预设分析：复杂PCI围术期心肌损伤、微轴流泵与心血管死亡
SRSD216 – A Once Yearly Novel Small Interfering RNA Therapeutic to Lipoprotein(a) Provides Time Averaged Annualized Reduction of 85% After a Single Dose - A Phase 1 Study
SRSD216Ⅰ期试验：一款每年只需给药一次的Lp(a)小干扰 RNA 疗法：单次给药后，Lp(a)年度平均降幅可达85%
RN0361 – a Novel Quaternary Gal-NAc siRNA, for the Treatment of Hypertriglyceridemia: A Phase 2a, Placebo-Controlled, Single Dose, Parallel Group Study
RN0361 Ⅱa 期、安慰剂对照、单次给药、平行组研究：新型四价GalNAc siRNA用于高甘油三酯血症治疗的安全性和有效性
First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia
靶向PCSK9与APOC3的双功能RNAi类药物用于治疗混合型
RESOLVE-1 – Anti-Inflammatory Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast: Results From the Phase 2 RESOLVE-1 Trial
RESOLVE 1Ⅱ期试验：口服NLRP3抑制剂Ruvonoflast的抗炎与安全性结果
Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction With Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of SHASTA-3 and SHASTA-4
SHASTA-3与SHASTA-4研究汇总分析：Plozasiran用于重度高甘油三酯血症治疗时，甘油三酯与
Lipoprotein(a), Aspirin and Cardiovascular Events in Older Adults
在老年人中，探究Lp(a)、
LINKED-BP – Home Blood Pressure Telemonitoring Linked With Community Health Workers to Improve Blood Pressure: The LINKED-BP Program Cluster-Randomized Controlled Trial
LINKED BP整群随机对照试验：家庭血压远程监测联动社区卫生工作者改善血压控制
The Effect of a Community-Based Cardiovascular Health Intervention in Black Men on Life’s Essential 8 and Perceived Stress: Black Impact
Black Impact试验：黑人男性社区心血管健康干预对心血管健康八大要素（Life’s Essential 8）及感知压力的影响
PMHH -The Penn Medicine Healthy Heart Trial: Reducing Clinician Burden for ASCVD Risk Management
PMHH（宾大医学院健康心脏）试验：减轻ASCVD风险管理给临床医师带来的工作负担
ADHERE-ASCVD – Digital Outreach Modalities to Improve Statin Refill Adherence Across the Age Spectrum: Insights From the ADHERE-ASCVD Randomized Clinical Trial
ADHERE ASCVD随机试验：不同年龄段人群应用数字化触达方式提升他汀续方依从性
Cleaner Air for Lower Cardiometabolic Risk: A Randomized, Double-Blind, Sham-Controlled Trial of Air Pollution Reduction
一项减少空气污染的随机、双盲、假干预对照试验：减少空气污染以降低心血管代谢风险的疗效探究
IRONMET-HFpEF – Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Trial Primary Results
IRONMET-HFpEF试验主要结果：静脉补铁对射血分数保留的心衰（HFpEF）运动不耐受机制的影响
SUMMIT – Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction
SUMMIT试验：
DAPARHT – Dapagliflozin for Renal Protection in Heart Transplant Recipients
DAPARHT试验：
CADENCE – Effects of Sotatercept on Cardiac Structure and Function: Analysis of the CADENCE Study
CADENCE研究分析：Sotatercept对心脏结构与功能的影响
ELPIS II – A Phase 2b Randomized Clinical Trial to Evaluate the Efficacy and Safety of Laromestrocel as Adjunct Therapy During Stage II Palliation for Hypoplastic Left Heart Syndrome
ELPIS II Ⅱb期随机临床试验：评估Laromestrocel作为左心发育不良综合征Ⅱ期姑息手术辅助治疗疗效与安全性
Semaglutide Ameliorates the Seminal Hemodynamic Features of Obesity-Related HFpEF: A Placebo Controlled Randomized Clinical Trial
一项安慰剂对照随机临床试验：
CATCH – Single-Pill Combination Strategy for Hypertension Control in Resource-Constrained Settings: A Cluster-Randomized Trial
CATCH整群随机试验：资源匮乏地区采用单片复方制剂策略控制
TRANSFORM-HTN – Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
TRANSFORM HTN试验：新型醛固酮合酶抑制剂Lorundrostat用于未控制高血压治疗的长期疗效与安全性
Angiotensinogen RNA Interference With LDR2402 for Hypertension
LDR2402试验：靶向血管紧张素原的RNA干扰疗法用于高血压治疗
Optimization of Atherogenic Lipid Management With RN5681, a Bivalent SiRNA Targeting PCSK9 and Lp(a)
使用靶向PCSK9和Lp(a)的双siRNA药物，治疗RN5681优化动脉粥样硬化性脂质管理
FB7023, a Novel Dual-Targeting siRNA Against PCSK9 and Lpa, Simultaneously Reduces Both LDL-C and Lp(a), Exhibiting High-Value Treatment Potential for Management of ASCVD
FB7023是一种针对PCSK9和LPA的新型双靶点siRNA，可同时降低LDL-C和Lp(a)，在管理动脉粥样硬化性心血管疾病（ASCVD）方面展现出高价值的治疗潜力
Prospective In Silico Prediction of the Lp(a) HORIZON Trial Using a Mechanistic Atherosclerotic Cardiovascular Disease Model
使用机制性ASCVD模型对Lp(a) HORIZON试验进行前瞻性计算机模拟预测
Frenchie Lpa - Variability of Lipoprotein(a) Measurement Between Acute Myocardial Infarction at Admission, Discharge and Follow Up
Frenchie Lpa试验：急性心梗入院、出院及随访期间Lp(a)测量的变异性
DETECT-HF - Results of a Prospective, International, Multicenter, Pivotal Validation Study of Remote Voice Analysis for Monitoring Ambulatory Heart Failure Patients
DETECT HF前瞻性国际多中心关键验证试验结果：远程语音分析用于门诊心衰患者监测
BETTER CARE-HF – Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations for Heart Failure (BETTER CARE-HF) Multi-Center Trial: A Pragmatic Cluster Trial of an Ambulatory Alert Across Multiple Health Systems
BETTER CARE-HF 多医疗体系下门诊预警系统的实用性整群试验：搭建电子工具强化心衰心血管指南推荐
A Multi-Center Randomized Controlled Trial of a Digital Health Intervention for Medication Optimization in Heart Failure
一项多中心随机对照试验：数字化健康干预用于
PHARM-HF 2 - Randomized Evaluation of Education and Feedback and Referral Nudges to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Healthcare System
PHARM-HF 2试验随机研究：评估教育、反馈及转诊提示策略提升美国退伍军人医疗体系基层药师心衰药物优化能力
HELIOS-B - 2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
HELIOS-B试验：Vutrisiran治疗ATTR-CM开放标签延长期2年结果
HELIOS-B CPET - The Effect of Vutrisiran on Exercise Capacity and Ventilatory Efficiency: Insights From the HELIOS-B CPET and Stress Echocardiography Subgroup Analysis
HELIOS-B CPET分析：Vutrisiran对运动耐量及通气效率的作用（CPET+负荷超声亚组）
CARDIO-TTRansform - Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy - Insights From the CARDIO-TTRansform Trial
CARDIO-TTRansform分析：Eplontersen改善与ATTR-CM患者的心脏结构及功能
CARDIO-TTRansform CMR - Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy
CARDIO-TTRansform CMR试验：Eplontersen治疗后的的心肌应答
VESALIUS-CV – Health Economic Outcomes in the Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Randomized Trial
VESALIUS-CV随机试验：
Lp(a)FRONTIERS EXPANSION – Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants With Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease
Lp(a)FRONTIERS EXPANSION试验：Pelacarsen 用于Lp(a)升高且合并ASCVD的黑种人/非裔及拉丁裔受试者的疗效与安全性
T2T – Test 2 Treat: A Hybrid Effectiveness-Implementation Trial to Improve LDL-C Testing and Management After Hospitalization for Atherosclerotic Cardiovascular Disease
T2T试验：优化ASCVD住院后患者LDL-C检测与管理的混合有效性实施试验
TIME-SGLT2 TrialTreating the Metabolic Syndrome With a Sodium-Glucose Cotransporter-2 Inhibitor: A Randomised Controlled Trial
TIME SGLT2随机试验：SGLT2抑制剂用于
ECG-AI-First Sequential Screening With NT-proBNP for Heart Failure Risk: The HeartShare/AMP-HF Pooled Cohort Study
HeartShare与AMP HF合并队列 AI心电图联合NT proBNP序贯筛查心衰风险
HeartShare/AMP-HF汇总队列试验：ECG-AI-First序贯筛查策略联合NT-proBNP评估心力衰竭风险
Recover-Autonomic - Results From Primary Analysis of the Coordinated versus Usual Nonpharmacologic Care for Postural Orthostatic Tachycardia Syndrome in Long COVID: A Pooled Analysis From the Recover-Autonomic Platform Trial
RECOVER-Autonomic平台试验汇总分析：长新冠相关
PROGRESS - Transcatheter Aortic Valve Replacement or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results From the Progress Randomized Trial
PROGRESS随机试验主要结果：中度
MITIGATE - Early Percutaneous Mitral Commissurotomy versus Conventional Management for Asymptomatic Severe Mitral Stenosis: Final Outcomes of the MITIGATE Trial
MITIGATE试验最终结局：在无症状重度
PREOP-ECHO - Routine Preoperative Echocardiography Before Intermediate-Risk Noncardiac Surgery: The PREOP-ECHO Randomized Clinical Trial
PREOP-ECHO随机试验：中风险非心脏手术前常规超声心动图
Rapid- Water-Flow - Phase 3 Multicenter Trial of Automated Point-of-Care Oxygen-15 Water Positron Emission Tomography Myocardial Perfusion Imaging for the Detection of Coronary Artery Disease: The Rapid- Water-Flow Trial
Rapid-Water-Flow试验：自动化床旁氧-15水PET心肌灌注显像诊断冠心病的Ⅲ 期试验
RPA-PMI - Active Surveillance for Perioperative Myocardial Infarction/Injury With Robotic Process Automation: A Double-Blind Randomized Controlled Implementation Trial (RPA-PMI)
RPA-PMI双盲随机对照实施试验：基于机器人流程自动化主动监测围术期心肌梗死与损伤
Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period
BHB与HRS 1893研究 梗阻性肥厚型心肌病52周延长期疗效与安全性
BHB/HRS-1893用于梗阻性HCM 52周延长期的疗效与安全性
Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The Acacia-HCM CMR Study
ACACIA-HCM CMR试验：Aficamten改善非梗阻性HCM心脏结构与功能
Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy
Aficamten 对非梗阻性 HCM 患者报告健康状况的作用
Outcomes of Mavacamten Treatment in Adolescents With Obstructive Hypertrophic Cardiomyopathy at 56 Weeks: The SCOUT-HCM Trial
SCOUT HCM研究 青少年梗阻性肥厚型心肌病Mavacamten治疗56周结局
SCOUT-HCM试验：青少年梗阻性HCM应用玛伐凯泰56周结局
A Randomized Trial of Sacubitril/Valsartan versus Enalapril in Chronic Chagas Cardiomyopathy With Reduced Ejection Fraction: Results of the ANSWER-HF Biomarker Subanalysis
ANSWER HF生物标志物亚分析结果：在慢性Chagas心肌病患者中，进行沙库巴曲缬沙坦与依那普利的疗效对比
Multicenter Evaluation and Geographic Validation of a Risk-Guided Strategy for Prioritizing Cardiovascular Diagnostic and Specialist Care in Resource-Limited Health Systems
在资源受限的地区，基于风险分层策略分配心血管检查与专科资源的多中心验证
Digital Health Intervention to Optimize Heart Failure Management After Hospital Discharge in Brazil: A Randomized Clinical Trial (OPT-HF)
OPT-HF随机试验：巴西心衰出院后数字化干预的随机对照试验
Multicenter Implementation of a Competency-Based Echocardiography Delivery Model With AI-Assisted Acquisition and Remote Cardiologist Interpretation
AI辅助图像采集联合远程心内科判读的超声心动图服务多中心实施模式研究
The Optimal Lipid Marker for Cardiovascular Risk- Findings From Large South Asian CARRS Cohort
CARRS大规模南亚队列试验：心血管风险评估的最优脂质标志物
Intensive versus Standard Blood-Pressure Control Among 13,844 Patients With Stroke, Transient Ischemic Attack, or Type 2 Diabetes: Main Results of the OPTIMAL-Program
OPTIMAL-Program试验（13844例患者）主要结果：卒中、短暂性脑缺血发作（TIA）或2型糖尿病患者强化降压与标准降压的比较
Accuracy of Community Health Worker-Led Out-of-Office Blood Pressure Measurement in Two Rural Sub-Saharan African Populations (IHCoR (Improving Hypertension Control in Rural Sub-Saharan Africa))
IHCoR试验：在撒哈拉以南非洲的两处农村人群中，探究由社区卫生工作者完成的院外血压测量的准确性
信源：AHA 官网
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
我要投稿
